Favrille, Inc. To Host Conference Call And Live Webcast To Discuss Third Quarter 2005 Financial Results On Wednesday, November 2, 2005

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing targeted immunotherapies for cancer and diseases of the immune system, announced today that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, November 2, 2005 to discuss the Company's third quarter financial results. John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille, will also present an update on the Company. A press release reporting the Company's third quarter financial results will be issued before the U.S. stock markets open on Wednesday, November 2, 2005.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO )

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of Favrille's corporate web site at www.favrille.com. Alternatively, callers may participate in the conference call by dialing 866.356.3377 (domestic) or 617.597.5392 (international). The passcode for the conference call is 27965216. A telephone replay of the call will also be available for 48 hours. Callers may access the telephone replay by dialing 888.286.8010 (domestic) or 617.801.6888 (international), passcode 60929803.

About Favrille, Inc.

Favrille, Inc. (www.favrille.com) is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.

CONTACT: Pete De Spain, Associate Director, Investor Relations ofFavrille, Inc., +1-858-526-2426, pdespain@favrille.com

Back to news